Disease · EFO_0004920

progression free survival

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. progression free survival. Diseases, record EFO_0004920. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004920

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: progression free survival
Open Targets ID: EFO_0004920
Other names: time before disease progression
Highest stage of its drugs: Phase 2, for 28 of its 28 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs28

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	1	Drugs and targets
ABEMACICLIB	CHEMBL3301610	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ALECTINIB	CHEMBL1738797	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
APALUTAMIDE	CHEMBL3183409	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
BRENTUXIMAB VEDOTIN	CHEMBL1742994	Antibody drug conjugate	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CARBOPLATIN	CHEMBL1351	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
COBIMETINIB	CHEMBL2146883	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DABRAFENIB	CHEMBL2028663	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 28

See all 28 drugs

Targets53

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
BRAF	Serine/threonine-protein kinase B-raf	3	Serine/threonine-protein kinase B-raf inhibitor	Phase 2	https://conductscience.org/library/genes/673	Drugs and targets
TUBA1A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	3	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 53

See all 53 targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03141359	Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC	Phase 2	61	2024-08-29	Lung Cancer Stage II, Lung Cancer Stage III, Non Small Cell Lung Cancer	CARBOPLATIN, CISPLATIN, DURVALUMAB, ETOPOSIDE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT07490210	Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer	Phase 2	300		Oligometastatic Prostate Cancer	REZVILUTAMIDE	Its record names the disease	ClinicalTrials.gov
NCT05159245	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs	Phase 2	250		Advanced Cancer, Solid Tumor, Haematological Malignancy	ABEMACICLIB, ALECTINIB, APALUTAMIDE, ATEZOLIZUMAB, COBIMETINIB, DABRAFENIB, ENTRECTINIB, PEMIGATINIB, PERTUZUMAB, REGORAFENIB, TEPOTINIB, TRAMETINIB, TRASTUZUMAB, VEMURAFENIB, VISMODEGIB	Its record names the disease	ClinicalTrials.gov
NCT03668730	Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma	Phase 2	215		Nasopharyngeal Carcinoma	CISPLATIN, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT02292979	Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.	Phase 2	170		Hodgkin Lymphoma	BRENTUXIMAB VEDOTIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE	Its record names the disease	ClinicalTrials.gov
NCT04933669	Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors	Phase 2	122		Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials4

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39620432	DERIVED	1	PubMed
39615497	DERIVED	1	PubMed
37801967	DERIVED	1	PubMed
35867960	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004920

GET https://conductscience.org/api/diseases/v1/EFO_0004920/drugs?page=2

API reference For AI assistants